GTC
AQST icon

Ghost Tree Capital’s Aquestive Therapeutics AQST Stock Holding History

Ghost Tree Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-702,941
Closed -$2.99M – 66
2024
Q1 		$2.99M Buy
+702,941
New +$2.34M 0.83% 41

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ghost Tree Capital's AQST Position: Q2 2024 in Review

Ghost Tree Capital sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 702,941 shares — an estimated $2.99M sold.

Ghost Tree Capital first reported a position in AQST in Q1 2024 and held it in 1 quarter. The position peaked at $2.99M in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

  • Ghost Tree Capital reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 702,941 Aquestive Therapeutics shares in Q2 2024, an estimated $2.99M.
  • Ghost Tree Capital first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 1 quarter.
  • Ghost Tree Capital's Aquestive Therapeutics position peaked at $2.99M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.